Compounded tirzepatide with B12: what the TikTok dose diary leaves out

What did @lovethyliverr actually say?

The creator documented her fourth 2.5 mg dose of compounded tirzepatide mixed with B12, injected subcutaneously into the back of her arm using a claw clip to pinch the skin solo. She drew up 50 units from a vial, cleaned the top before drawing, let the medication reach room temperature first, and attributed her lack of bruising to that warm-up step. She's moving to 5 mg next week and reported minimal nausea through her first month.

The video is a technique tutorial as much as a journey update. She walks through her prep sequence step by step: air bubble return to vial, skin pinch, injection, and cap replacement. For 66,000 viewers watching someone self-inject a GLP-1 receptor agonist for the first time, the details here actually matter.

Does the science back this up?

Some of it, yes. The room temperature claim has plausible biological logic, and the basic injection technique is reasonable, but several steps in her sequence raise real concerns.

On room temperature: cold injectable medications can cause more local discomfort and tissue irritation. A 2019 review in Diabetes Technology and Therapeutics (Frid et al.) confirmed that cold insulin injections increase pain and can affect absorption rates. While that's insulin, not tirzepatide, the underlying subcutaneous tissue physiology is similar enough that the logic holds. Credit where it's due.

On the air-back-into-vial technique: this is where things get shakier. Injecting air into a multi-dose vial before drawing medication is a standard pharmacy technique for pressure equalization, but the sequence she describes, drawing back to 50 units then pushing air in, then pulling medication, suggests she may be conflating steps. Done incorrectly, this can introduce air into the syringe barrel or create dosing inaccuracies. No study exists specifically on home GLP-1 vial technique errors, but medication preparation errors in home settings are well-documented (Dayer et al., 2013, BMJ Quality and Safety).

What did they get right and wrong?

Right: letting medication reach room temperature, cleaning the injection site, using a skin pinch for subcutaneous placement, and rotating sites. These are genuinely solid practices that align with subcutaneous injection guidelines from the Forum for Injection Technique.

Wrong, or at least incomplete: the air bubble technique she describes is confusingly explained and could mislead viewers into incorrect vial handling. More importantly, she's injecting compounded tirzepatide with B12 added. That combination is not FDA-approved in any formulation. Compounded tirzepatide is not the same as Zepbound or Mounjaro, and adding B12 to a GLP-1 peptide vial introduces sterility and stability variables that no peer-reviewed literature has examined in home-use settings.

She also says this is her first month and frames dose escalation as straightforward. Tirzepatide dose titration is supposed to be supervised. The 2.5 mg to 5 mg escalation schedule in the Zepbound prescribing information assumes a prescriber is monitoring tolerability. Watching one creator's experience is not a substitute for that oversight.

What should you actually know?

Compounded tirzepatide exists in a complicated regulatory space. The FDA placed tirzepatide on its shortage list, which allowed 503A and 503B compounding pharmacies to produce it legally for a period. That status has been contested and updated multiple times through 2024 and into 2025. Compounded versions are not FDA-evaluated for safety, efficacy, or sterility on an individual batch basis.

Adding B12 to compounded tirzepatide is a common practice at some compounding pharmacies, marketed as reducing injection site discomfort or supporting energy. There is no clinical trial evidence supporting B12 addition to tirzepatide formulations, and the stability of that combination in a shared vial has not been published in peer-reviewed literature.

The arm injection site she prefers is actually a legitimate option. Subcutaneous injections in the posterior upper arm are used for insulin and other injectables. A 2016 study in Diabetes Care (Hirsch et al.) confirmed similar absorption profiles across abdomen, thigh, and arm sites for subcutaneous delivery. Her preference is fine, but it does require good technique when self-injecting, and the claw clip method, while creative, is not a clinically validated approach.

Bottom line for FormBlends users

The creator is not a medical professional, and this video is personal documentation, not instruction. Some of her technique points are reasonable. Others, particularly the vial handling sequence and the B12 combination, are either unclear or unsupported by evidence. If you're using compounded tirzepatide, your injection technique, dosing schedule, and any additive combinations should come from the provider who prescribed it, not from TikTok tutorials with 66,000 views.